21.66
8.30%
1.66
시장 영업 전:
21.31
-0.35
-1.62%
전일 마감가:
$20.00
열려 있는:
$20.2
하루 거래량:
293.85K
Relative Volume:
1.17
시가총액:
$641.07M
수익:
$4.12M
순이익/손실:
$-56.68M
주가수익비율:
-3.9077
EPS:
-5.5429
순현금흐름:
$-51.44M
1주 성능:
+8.98%
1개월 성능:
-8.99%
6개월 성능:
-18.45%
1년 성능:
+81.26%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
857-201-2700
주소
300 TECHNOLOGY SQUARE, CAMBRIDGE
DNTH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
21.66 | 641.07M | 4.12M | -56.68M | -51.44M | -5.5429 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-20 | 개시 | TD Cowen | Buy |
2024-10-03 | 개시 | Oppenheimer | Outperform |
2024-07-26 | 개시 | Robert W. Baird | Outperform |
2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
2024-05-16 | 개시 | H.C. Wainwright | Buy |
2024-02-15 | 개시 | Stifel | Buy |
2023-12-26 | 개시 | Jefferies | Buy |
2023-11-22 | 개시 | Wedbush | Outperform |
2023-10-30 | 개시 | Guggenheim | Buy |
2023-09-28 | 개시 | Raymond James | Outperform |
2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
2021-08-20 | 재개 | Goldman | Neutral |
2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-07-22 | 재확인 | B. Riley Securities | Buy |
2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
2021-06-15 | 개시 | BTIG Research | Buy |
2021-05-18 | 개시 | B. Riley Securities | Buy |
2021-01-07 | 개시 | Mizuho | Buy |
2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest - MarketBeat
A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5%Here's Why - MarketBeat
Barclays PLC Purchases 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Barclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Dianthus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8%Here's What Happened - MarketBeat
Jane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stake Trimmed by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Raised by Barclays PLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 2.5%Here's Why - MarketBeat
State Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
State Street Corp Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
TD Cowen Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen - MarketBeat
Wellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James - Defense World
Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
MetLife Investment Management LLC Purchases 7,854 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Janus Henderson Group PLC Acquires 273,670 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
30,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Purchases New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asia Singapore Pte. Ltd. - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Quest Partners LLC Has $31,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Braidwell LP Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Vestal Point Capital LP - MarketBeat
Great Point Partners LLC Lowers Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5.1%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1%Should You Sell? - MarketBeat
What is HC Wainwright's Estimate for DNTH FY2024 Earnings? - MarketBeat
Raymond James Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock - Defense World
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts - Benzinga
Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright - MarketBeat
Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade - Defense World
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):